In the previous study, 5 cases (31.25%) showed GLI1 activation within the Hh pathway, including 2 (12.5%) with GLI1 amplification and 3 (19.75%) with MALAT1-GLI1 oncogenic fusions.[27] Banerjee et al[28] reported the first report of recurrent PTCH1 loss in PF based on next generation sequencing and proposed that targeted Hh pathway inhibition with SMO antagonists might represent a target for treating a subset of PF. The gene discussed is SMO; the disease is pemphigus foliaceus.